Eight research questions relating to comorbidities in patients with RA, PsA, or PsO formulated by the Canadian Dermatology-Rheumatology Comorbidity Initiative.
| Question | Description |
|---|---|
| 1. | What are the risks of CVD in patients with RA, PsA, and PsO, including the effect of disease severity, disease duration, and comparison with traditional CV risk factors? |
| 2. | Does the treatment of RA, PsA, and PsO with systemic agents have an effect on CV outcomes? |
| 3. | Smoking: What is the prevalence of smoking in patients with RA, PsA, or PsO? What effect does smoking have on disease activity? What is the efficacy of smoking cessation strategies in terms of disease activity and response to treatment? |
| 4. | Weight: Does weight/BMI relate to disease activity in RA, PsA, and PsO? What is the effect of treatment on weight? What is the effect of weight on response to treatment? What is the effect of weight management on disease activity? |
| 5. | Other comorbidities: Are there any differences in malignancies and infections between patients with RA, PsA, and PsO? How common are malignancies and infections in these populations? What is the effect of treatment on malignancies and infections? |
| 6. | Malignancies: Is there an increased risk of cancer recurrence or new cancers in patients with RA, PsA, or PsO with previous cancer treated with traditional DMARD or biologic DMARD? |
| 7. | Osteoporosis: Is osteoporosis related to disease activity and biomarkers? What is the effect of treatment on osteoporosis? |
| 8. | Depression: What is the prevalence of depression in patients with RA, PsA, or PsO? What are the risk factors for depression? What is the effect of treatment on depression? |
RA: rheumatoid arthritis; PsA: psoriatic arthritis; PsO: psoriasis; CVD: cardiovascular diseases; CV: cardiovascular; BMI: body mass index; DMARD: disease-modifying antirheumatic drugs.